Shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) have earned an average recommendation of “Hold” from the twenty-three research firms that are presently covering the firm, MarketBeat.com reports. Four investment analysts have rated the stock with a sell recommendation, thirteen have issued a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $16.90.

VRX has been the subject of several research reports. Jefferies Group LLC set a $18.00 price objective on shares of Valeant Pharmaceuticals International and gave the company a “buy” rating in a research note on Saturday, May 6th. J P Morgan Chase & Co set a $10.00 price target on shares of Valeant Pharmaceuticals International and gave the company a “hold” rating in a research note on Monday, July 17th. Piper Jaffray Companies reissued an “underweight” rating and issued a $10.00 price target on shares of Valeant Pharmaceuticals International in a research note on Friday, July 14th. Guggenheim assumed coverage on shares of Valeant Pharmaceuticals International in a report on Saturday, June 17th. They issued a “buy” rating and a $18.00 price objective on the stock. Finally, Stifel Nicolaus restated a “buy” rating and issued a $35.00 price objective on shares of Valeant Pharmaceuticals International in a report on Monday, July 17th.

In related news, Director Schutter Richard U. De bought 20,000 shares of the stock in a transaction that occurred on Thursday, May 11th. The stock was purchased at an average cost of $13.90 per share, for a total transaction of $278,000.00. Following the completion of the acquisition, the director now owns 70,572 shares in the company, valued at $980,950.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 5.87% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in the stock. Sigma Planning Corp bought a new stake in Valeant Pharmaceuticals International during the first quarter worth about $184,000. Nationwide Fund Advisors increased its stake in Valeant Pharmaceuticals International by 3.8% in the first quarter. Nationwide Fund Advisors now owns 51,500 shares of the specialty pharmaceutical company’s stock valued at $568,000 after buying an additional 1,900 shares in the last quarter. Cambridge Advisors Inc. increased its stake in Valeant Pharmaceuticals International by 0.6% in the first quarter. Cambridge Advisors Inc. now owns 12,650 shares of the specialty pharmaceutical company’s stock valued at $140,000 after buying an additional 75 shares in the last quarter. Columbus Circle Investors increased its stake in Valeant Pharmaceuticals International by 24.6% in the first quarter. Columbus Circle Investors now owns 75,252 shares of the specialty pharmaceutical company’s stock valued at $830,000 after buying an additional 14,880 shares in the last quarter. Finally, Academy Capital Management Inc. TX increased its stake in Valeant Pharmaceuticals International by 19.5% in the first quarter. Academy Capital Management Inc. TX now owns 641,738 shares of the specialty pharmaceutical company’s stock valued at $7,078,000 after buying an additional 104,844 shares in the last quarter. Hedge funds and other institutional investors own 50.42% of the company’s stock.

Valeant Pharmaceuticals International (VRX) traded down 0.57% during trading on Monday, hitting $17.40. The stock had a trading volume of 3,621,372 shares. The stock’s market cap is $6.05 billion. Valeant Pharmaceuticals International has a 12 month low of $8.31 and a 12 month high of $32.74. The firm has a 50 day moving average of $15.10 and a 200-day moving average of $13.25.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last posted its earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported $2.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.87 by $1.93. The company had revenue of $2.11 billion during the quarter, compared to the consensus estimate of $2.17 billion. Valeant Pharmaceuticals International had a negative net margin of 14.96% and a positive return on equity of 58.02%. The firm’s quarterly revenue was down 11.1% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.08) earnings per share. Equities analysts predict that Valeant Pharmaceuticals International will post $3.89 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This article was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/07/24/valeant-pharmaceuticals-international-inc-nysevrx-receives-average-recommendation-of-hold-from-brokerages.html.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.